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ABSTRACT
Heart failure (HF) is a common cause of hospitalization and mortality in
older adults. HF is almost always embedded within a larger pattern of
multimorbidity, yet many studies exclude patients with complex
psychiatric and medical comorbidities or cognitive impairment. This has
left significant gaps in research on the problems and treatment of patients
with HF. In addition, HF is only one of multiple challenges facing patients
with multimorbidity, stressful socioeconomic circumstances, and
psychosocial problems. The purpose of this study is to identify
combinations of comorbidities and health disparities that may affect HF
outcomes and require different mixtures of medical, psychological, and
social services to address. The syndemics framework has yielded
important insights into other disorders such as HIV/AIDS, but it has not
been applied to the complex psychosocial problems of patients with HF.
The multimorbidity framework is an alternative approach for
investigating the effects of multiple comorbidities on health outcomes. The
specific aims are: (1) to determine the coprevalence of psychiatric and
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medical comorbidities in patients with HF (n = 535); (2) to determine
whether coprevalent comorbidities have synergistic effects on
readmissions, mortality, self-care, and global health; (3) to identify
vulnerable subpopulations of patients with HF who have high
coprevalences of syndemic comorbidities; (4) to determine the extent to
which syndemic comorbidities explain adverse HF outcomes in
vulnerable subgroups of patients with HF; and (5) to determine the effects
of multimorbidity on readmissions, mortality, self-care, and global health.
Study Registration: clinicaltrials.gov identifier: NCT04637776.
KEYWORDS: comorbidity; health status disparities; heart failure; mental
disorders; multimorbidity; patient readmission;
management; social determinants of health; syndemic
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ABBREVIATIONS
AICD, automatic implantable cardioverter defibrillator; BNP, brain
natriuretic peptide; BUN, blood urea nitrogen; CABG, coronary artery
bypass graft surgery; COPD, chronic obstructive pulmonary disease; DSM5, Diagnostic and Statistical Manual, 5th edition; eGFR, estimated
glomerular filtration rate; EMR, electronic medical record; ESC, European
Society of Cardiology; HF, heart failure; HFmrEF, heart failure with midrange ejection fraction; HFpEF, heart failure with preserved ejection
fraction; HFrEF, heart failure with reduced ejection fraction; HIV/AIDS,
human immunodeficiency virus/acquired immunodeficiency syndrome;
LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction;
MI, myocardial infarction; MD, major depression; NHLBI, National Heart,
Lung, and Blood Institute; NT-proBNP, N-terminal pro-brain natriuretic
peptide; NYHA, New York Heart Association; OSA, obstructive sleep apnea;
PCI, percutaneous coronary intervention; PSS, Perceived Stress Scale;
PTSD, posttraumatic stress disorder; SBT, Short Blessed Test; SDOH, social
determinants of health; TB, tuberculosis
INTRODUCTION
More than six million Americans have heart failure (HF), and the
prevalence is expected to increase 46% by 2030. HF is one of the most
common causes of hospitalization, impairment, and mortality in older
adults. The annual cost of HF care is expected to increase 127% by 2030, to
almost $70 billion in current dollars [1].
One of the reasons why HF is so burdensome and costly is that it is
usually complicated by multimorbidity [2], especially in older patients [3].
Both cardiovascular and noncardiovascular disorders that are risk factors
for HF tend to persist after HF has developed, and additional comorbidities
tend to accumulate as patients age. Unfortunately, most HF treatment
trials, as well as many other studies of HF, have excluded patients with
complex medical and psychiatric comorbidities, physical or cognitive
impairments, or frailty. This has left large gaps in research on the care of
older adults with HF [4].
Many epidemiological and clinical studies have focused on common
comorbidities in HF. Some have been broad investigations of multiple
disorders (e.g., [5–7]), but most have focused on specific illnesses. This
applies both to medical comorbidities such as diabetes [8] and psychiatric
comorbidities such as depression [9]. In addition, research on
socioeconomic factors [10] and health disparities [11]. In HF has not been
closely integrated with research on comorbidities in HF. Because HF
research is often confined to silos, little is known about interrelationships
among socioeconomic factors, disparities, and comorbidities in HF.
HF may be only one of several difficult challenges for patients with
multimorbidity, stressful socioeconomic circumstances, and psychosocial
problems [12]. Unfortunately, the fragmentation of research on HF has left
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us with little understanding of patients with such varied and complex
health needs. The purpose of this study is to identify disparities and
patterns of comorbidity that may affect the course of HF and that may
require different mixtures of medical, psychological, and social services to
address. It will encompass both psychiatric and medical comorbidities but
will emphasize psychiatric comorbidities.
Syndemics theory is a conceptual framework for studying this type of
psychosocial and medical complexity. Syndemics, also known as
synergistic epidemics, occur when there are adverse interactions between
coprevalent disorders. Syndemic disorders tend to concentrate in
populations that are made vulnerable by social determinants of health
(SDOH) [13]. The syndemics framework has yielded important insights
into other disorders such as HIV/AIDS, but it has not been applied to the
complex problems of patients with HF. The multimorbidity construct
provides an alternative approach for investigating the effects of multiple
comorbidities on health-related outcomes. This study will be the first to
use both the syndemics and multimorbidity frameworks to examine the
effects of SDOH, psychiatric comorbidities, and interactions between them,
on readmissions, self-care, and global health in patients with HF.
SIGNIFICANCE
Background
This project addresses the psychosocial and medical complexity of
patients with HF. This is significant because socioeconomic disadvantages,
health disparities, and multimorbidity complicate the course, treatment,
and cost of HF and other chronic illnesses [14]. There has been little if any
research on the syndemics of HF comorbidities, but there have been
numerous studies of HF risk factors, comorbidities, and vulnerability
factors. The following review focuses on studies that are relevant to this
project.
Race and Sex Disparities
Black men have worse HF outcomes than other groups defined by race
and sex. A study of over 55 million Medicare beneficiaries found higher
age-adjusted HF hospitalization rates in black men than in other groups
[15]. This was recently replicated in a study of 1.7 million hospital stays in
the US National Inpatient Sample [16]. Racial disparities in HF outcomes
are present even among insured patients [17,18].
Socioeconomic Disparities
Socioeconomic status (SES) affects HF outcomes. In a national sample
of Medicare beneficiaries (n = 25,086) hospitalized with HF, patients in the
lowest SES category had a higher risk of readmission and mortality within
one year of discharge [19]. Among 1342 participants in the Atherosclerosis
Risk in Communities (ARIC) study with an initial HF hospitalization and a
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high level of comorbidity, those who lived in low-income neighborhoods
had a higher risk of rehospitalization or death compared to those in
higher-income neighborhoods [20]. Among 2331 participants in the Heart
Failure: A Controlled Trial Investigating Outcomes of Exercise Training
(HF-ACTION) trial, low income was associated with worse functional
capacity and quality of life, and it predicted all-cause hospitalization and
death over 2.5 years in a univariate analysis but was not significant in an
adjusted model [21]. A recent prospective study of 1802 patients with HF,
a high score on the UK. Index of Multiple Deprivation (IMD) predicted allcause hospitalization and mortality and a longer cumulative duration of
hospitalization over one year [22]. Socioeconomic disadvantage is also
associated with higher rates of cardiovascular health risk behaviors such
as smoking [23].
Whether a patient has health insurance and if so, which type, affects
HF outcomes. In a study of 4584 HF index admissions, the adjusted odds of
all-cause readmissions were 32% higher, and those of HF readmissions
were 68% higher, among Medicaid than commercially insured patients
[24]. A study of 558,904 patients with HF in the California Patient Discharge
Database compared 30-day readmission rates before vs after the federal
Hospital Readmissions Reduction Program (HRRP). The readmission rate
dropped among Medicare patients but not among patients with
commercial insurance [25]. A 2013 study of 60,814 patients in the National
Cardiovascular Data Registry found that 9.4% were uninsured, 19.7% had
public insurance, and 70.9% were privately insured. Uninsured patients
were younger, predominantly female, more likely to have HF, and less
likely to be treated with guideline-recommended medications than other
patients [26].
Psychiatric Comorbidities
Depression
Approximately 20% of patients with HF have comorbid major
depression MD [27], but we found that in 682 patients with HF, the
prevalence of MD differed by age and New York Heart Association (NYHA)
class; it was 67% in younger patients in Class IV (i.e., severe HF symptoms
and functional impairment) [28]. We also found that MD during the index
hospitalization predicted multiple readmissions over one year [29] and
decreased survival [9]. Other studies have also found that depression
increases the risk of hospitalization [30,31] and decreases survival [30–37]
in HF. Depression is also associated with poor physical [38–40] and
neurocognitive [41] functioning, medication nonadherence[42,43], and
poor HF self-care [44,45].
Anxiety
We conducted a retrospective cohort study (n = 236,079) of Veteran’s
Administration (VA) patients who were free of cardiovascular disease at
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baseline. Patients with an anxiety disorder, MD, or both were at higher
risk of incident HF compared to those with neither disorder [46]. Anxiety
may also have prognostic value in established HF [47,48], although some
studies have found that it does not have independent prognostic value
after adjusting for depression [36,49]. Similarly, anxiety is negatively
associated with HF self-care but depression appears to have a stronger
effect [50].
Posttraumatic stress disorder (PTSD)
Several studies of trauma-exposed populations have found increased
odds of incident cardiovascular disorders including HF. A prospective
study of 8248 VA patients found that PTSD increased the risk of HF [51]. A
retrospective study of 251 low-income, predominantly black HF patients
also found that PTSD was associated with an earlier onset of HF [52]. PTSD
was also associated with HF in the Canadian Community Health Survey (n
= 36,984) [53] as well as in a German community-based study (n = 3171)
[54]. In contrast, little is known about PTSD in patients with established HF.
Psychotic disorders
Few studies have examined associations between psychotic disorders
and HF outcomes. In a study of 611 black patients hospitalized with HF, 7%
had schizophrenia and 2% had bipolar disorder. Both conditions were
associated with a higher risk of 30-day readmission; neither predicted a
higher risk of mortality [55]. A study of 255 elderly patients with serious
mental illnesses and 533 nonaffected primary care patients found higher
rates of emergency department visits and longer lengths of stay for
medical hospitalizations in those with schizophrenia or bipolar disorder
even though the prevalence of HF and other major medical illnesses did
not differ [56]. An 11.5-year follow-up of the Baltimore Epidemiologic
Catchment Area Study found that participants with bipolar disorder had
an increased risk of myocardial infarction or HF [57]. A more recent
Danish population-based cohort study including 36,718 hospitalized with
incident HF found that patients with schizophrenia had a higher risk of
one-year mortality but no higher risk of rehospitalization [58].
Substance use disorders
Substance use disorders are prevalent comorbidities in HF. Some of
them contribute to precursors of HF such as hypertension and coronary
heart disease and/or to cardiomyopathies. Several substance use disorders
paradoxically predict better short-term HF outcomes, probably because
they accelerate the development of HF and thus are inversely associated
with age in patients with HF.
Several studies have shown that smoking is a risk factor or that
smoking cessation is a protective factor for incident HF [59,60]. The
OPTIMIZE-HF trial produced the first large-scale analysis of the effects of
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smoking in established HF. Out of 48,612 patients, 7743 (16%) were
smokers. Paradoxically, smokers had a lower mortality risk than
nonsmokers, probably because they were younger [61]. However, in the
Survival and Ventricular Enlargement (SAVE) trial (n = 2231), smoking
cessation predicted a 40% lower risk of all-cause mortality and a 30%
lower risk of myocardial infarction (MI), HF hospitalization, or death [62].
Smoking also predicts mortality in HF patients on heart transplant lists
[63]. A recent analysis of the National Inpatient Sample found a 15.5%
prevalence of tobacco use disorder in patients hospitalized with HF [64].
Although alcoholic cardiomyopathy has been recognized for decades as
a cause of HF [65], heavy alcohol consumption was not associated with an
increased risk for HF in the Framingham Heart Study [66]. There has been
little research on the prevalence or effects of alcohol use disorder in
established HF.
Stimulants contribute to the development and progression of HF [67,68].
A study of 11,258 patients with HF in the Acute Decompensated Heart
Failure National Registry Emergency Module found that 5.3% of patients
reported current or past stimulant use, and that stimulant use was
associated with worse left ventricular dysfunction [69]. A study of 590
outpatients with cardiomyopathy or HF at a regional health center found
that 38% used methamphetamine, and methamphetamine use was
associated with worse left ventricular dysfunction [70]. A retrospective
study of 141 patients hospitalized with HF in California found that
methamphetamine use was associated with a worse NYHA class [71]. A
recent study of 267 patients with HF, 90 of whom used cocaine, found that
the cocaine users had a lower risk of major adverse cardiovascular events
(MACE) than nonusers, probably because the cocaine users were 10 years
younger on average [72].
Among 10 million patients with HF in the Nationwide Inpatient Sample,
29,014 had opioid use disorder. Opioid use was associated with younger
age and lower risk of in-hospital mortality [73].
Medical Comorbidities
Common medical comorbidities in HF include hypertension, coronary
artery disease (CAD), cardiac arrhythmias, anemia, diabetes, chronic
obstructive pulmonary disease (COPD), obstructive sleep apnea (OSA),
osteoarthritis, and renal insufficiency [74]. HF is also associated with
dementia. Associations between HF and Alzheimer’s disease have been
found in large cohort studies [75–78]. Associations with other dementias
have also been found [77,78]. Both medical and psychiatric comorbidities
complicate the treatment of HF [5] and increase the risks of readmission
[20,79–81] and death [20,82,83].
Multimorbidity
Multimorbidity is common in HF [6,84,85]. Older patients tend to have
more comorbidities than younger patients, although the prevalence of
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comorbidities is increasing among younger patients [86]. In 122,630
Medicare beneficiaries with HF, 40% had >5 noncardiac comorbidities,
often in conjunction with one or more cardiac comorbidities [74].
According to the latest (2017) data from CMS, 29% of Medicare
beneficiaries have 2–3 chronic conditions, 21% have 4–5, and 17% have 6
or more [87]. Figure 1 displays the latest CMS data on numbers of
comorbid conditions in a variety of index conditions. More patients with
HF have >5 comorbidities than patients with any other index condition,
and very few cases of HF present with no comorbidities. Figures 2 and 3
illustrate the dramatic effects that multimorbidity has on Medicare
spending and 30-day readmissions, especially in patients with a total of >6
chronic conditions.

Figure 1. Comorbidity among chronic conditions for Medicate Fee-for-Service beneficiaries (2017) [87].
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Figure 2. Distribution of Medicare Fee-for-Service beneficiaries and Medicare spending by number of
chronic conditions (2017) [87].

Figure 3. Distribution of Medicare Fee-for-Service beneficiaries and 30-day Medicare hospital readmissions
by number of chronic conditions (2017) [87].
Like most multimorbidity research, the CMS analyses use a simple
count of chronic conditions to measure the level of multimorbidity. The
count in any given study depends on which (and how many) disorders are
counted. This differs across studies and areas of research. In the proposed
study, the comorbidities that will be examined in the syndemics analyses
will also comprise the multimorbidity count.
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An implicit assumption of multimorbidity counts is that comorbidities
have additive rather than synergistic effects. Figures 2 and 3 suggest that
linear additivity may be an oversimplification, in that outcomes are much
worse for patients with >6 conditions than for those with fewer. All
participants in our study will have HF, and the presence of HF counts
toward the overall burden of multimorbidity. Consequently, the cut point
of interest in our study is >5 comorbidities (not 6).
INNOVATION
This study will be the first to apply the syndemics framework to HF
research and one of the first tests of syndemics theory in any area of
behavioral medicine other than HIV/AIDS. It will serve as an example of the
potential of the syndemics framework to advance our understanding of the
adverse effects of health disparities and of psychosocial and medical
multimorbidity and will help to encourage further syndemics research in
cardiovascular behavioral medicine and in other areas of behavioral medicine.
The syndemics concept originated in the 1990’s, in the medical
anthropology literatures on substance abuse [88] and HIV/AIDS [89]. It was
initially used to investigate the convergence of these interrelated
epidemics in impoverished inner-city communities and in populations
that experience discrimination, stigma, abuse, or other forms of
victimization. It is still being applied to these areas of research, but
syndemics theory is also playing a growing role in other areas of
epidemiological and clinical research [13].
In a syndemic (synergistic epidemic), there are adverse interactions
between two coprevalent disorders that may increase the severity of one
or both. For example, HIV/AIDS and tuberculosis (TB) interact to cause
excess morbidity and mortality. AIDS increases the risk of incident TB,
infection with HIV predicts progression from TB infection to TB disease,
and TB is a frequent cause of death in HIV/AIDS. Both conditions require
complex medication regimens and pose high risks of nonadherence and
drug-drug interactions [90].
Syndemics theory also addresses the socioeconomic contexts of
coprevalent disorders. It predicts that they cluster within populations that
are vulnerable due to poverty, discrimination, lack of access to health care,
or other adverse social or socioeconomic circumstances [91]. Thus,
investigations of syndemics ask four interrelated questions: (1) Are the
disorders coprevalent? (2) Are there any adverse interactions between
them? (3) Do they cluster within vulnerable subpopulations? and (4) Do
these disease clusters help to explain why the vulnerable subpopulations
have worse health outcomes? The first and second questions are typically
addressed in the entire population of interest, which in our case consists
of patients with HF. When interacting disorders are found, then the third
and fourth questions are asked.
Regardless of whether two coprevalent disorders are more severe
when they occur jointly rather than alone, interactions between them may
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complicate other disorders with adverse effects that are worse than
additive. When the syndemics framework is used to study comorbidities
in a focal disorder such as HF, the conditions of interest must be
coprevalent not only with each other, but also with the focal disorder. In
addition, the “adverse interaction” questions concern potential impacts on
the focal disorder or on global health outcomes rather than on the severity
of the interacting comorbidities themselves. We may find, for example,
that depression and diabetes are coprevalent comorbidities in patients
with HF. Whether depression and/or diabetes are more severe in patients
with both comorbidities than in those with only one is not the key question.
The more important question is whether patients with both comorbidities
have worse HF outcomes than would be expected if depression and
diabetes had independent or additive effects.
It is important to note that adverse interactions and clustering within
vulnerable subgroups are hypotheses based on syndemics theory, not
foregone conclusions. We may find that some coprevalent comorbidities
do not interact, or that some comorbidities that do interact do not cluster
within vulnerable subgroups. We may also find that multimorbidity is a
more parsimonious explanation than syndemics for adverse HF outcomes.
However, so little is known about the impact of psychiatric comorbidities
other than depression in HF that this study will yield important new
information about them even if none are syndemic. We know little, for
example, about the characteristics of patients with HF who have comorbid
substance use disorders. Thus, the study will yield reportable results that
extend beyond our primary aims.
SPECIFIC AIMS
Modifications of Aims
We originally proposed to recruit, enroll, and assess patients with HF
during a hospital stay, and to examine 30-day readmissions as the primary
outcome. However, the COVID-19 pandemic started to disrupt research
and clinical operations at our medical center during the start-up phase of
the study. One of the consequences of this development was that it became
impossible to conduct this type of research with hospitalized patients.
Consequently, we revised the protocol and obtained approval for the
modified research plan from the National Heart, Lung, and Blood Institute
(NHLBI) and our institutional review board.
The modified plan is to use the hospital’s electronic medical record
(EMR) system to identify study candidates, recruit them within 30 days
after discharge via mail and telephone, and conduct the baseline
assessments via telephone. Because the baseline assessments will be
conducted during rather than before the 30-day post-discharge period, it
is no longer feasible to prospectively study 30-day readmissions. Instead,
we will study multiple readmissions over the entire follow-up phase. We
have also made some adjustments to the baseline assessment battery to fit
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these unanticipated circumstances. For example, we will use a different
dementia screener than originally planned; the Short Blessed Test (SBT)
can be administered over the telephone but the instrument we originally
planned to use is not suitable for telephone administration.
Also, the shift to remote recruitment and assessment creates the
possibility of recruiting patients from other hospitals. Initially,
recruitment will be restricted to one hospital, as originally planned. If we
receive permission from other hospitals, and if it is logistically feasible to
expand recruitment, we will do so.
Specific Aims (Revised)
1. To

determine

the

coprevalence

of

psychiatric

and

medical

comorbidities in patients with HF.
2. To test the hypotheses that coprevalent comorbidities have synergistic
effects on:
a. All-cause readmissions and mortality risk,
b. HF self-care, and
c.

perceived health.

3. To identify vulnerable subpopulations of patients with HF who have
higher coprevalences of syndemic comorbidities compared to less
vulnerable subpopulations.
4. To determine the extent to which syndemic comorbidities explain
adverse outcomes (readmissions and mortality, poor HF self-care, and
poor perceived health) in vulnerable subgroups of patients with HF.
5. To determine the effects of multimorbidity on readmissions, mortality,
self-care, and perceived health.
METHODS
Eligibility Criteria
HF Inclusion criteria
A daily query of the Epic EMR system at Barnes-Jewish Hospital at
Washington University Medical Center in St. Louis will identify patients who
meet the study’s HF inclusion criteria, which require that the patient (1) has
a documented clinical diagnosis of HF and (2) meets the European Society
of Cardiology (ESC) 2016 “signs and symptoms” criteria for the diagnosis of
HF on admission or during the hospital stay [92]. The ESC criterion requires
the presence of >2 typical symptoms and/or specific signs of HF. The typical
symptoms of HF include breathlessness, orthopnea, paroxysmal nocturnal
dyspnea, reduced exercise tolerance, fatigue, and ankle swelling. The
specific signs of HF include elevated jugular venous pressure, hepatojugular
reflux, third heart sound, and laterally displaced apical impulse. Patients
who meet these criteria will also meet the American College of Cardiology
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Foundation (ACCF)/American Heart Association (AHA) criteria for Stage C or
D heart failure. In addition, the eligibility criteria include patients with
preserved (HFpEF), mid-range (HFmrEF), and reduced (HFrEF) ejection
fraction. However, the objective is to enroll patients with chronic HF.
Consequently, cases of isolated right HF (cor pulmonale) or reversible HF
due to valve disease with impending surgical correction do not fit the study’s
eligibility criteria. Recruitment will be expanded to other hospitals in the St.
Louis area if and when feasible.
Exclusion criteria
Patients who meet any of the following exclusion criteria will not be
eligible to participate in the study: (1) Patient’s physician opposes study
participation; (2) patient or legally authorized representative (LAR)
refuses to participate; (3) patient is too ill to participate; (4) logistical or
communication barrier; (5) unavailable to participate within 30 days of
discharge from the index hospitalization.
Recruitment, Consent, and Assent
Patients with clinically diagnosed dementia
If a patient who meets the inclusion criteria has a diagnosis of any type
of dementia or other condition such as stroke or head injury that has
caused severe cognitive impairment, the study recruiter will contact the
patient’s LAR by mail and telephone, explain the study, and ask the LAR to
consent to the patient’s participation. The patient’s verbal assent will be
sought if the patient is able to cooperate. Patients with dementia or other
conditions that have caused severe cognitive impairment will be
exempted from the baseline interviews and questionnaires; the only data
to be obtained will be extracted from the EMR.
Patients without clinically diagnosed dementia
If a patient who meets the HF inclusion criteria does not have a clinical
diagnosis of dementia or other documented condition that has caused severe
cognitive impairment, the study recruiter will contact the patient by mail and
telephone, explain the study, and seek the patient’s consent to participate.
If there is any uncertainty as to whether the patient is sufficiently
cognitively intact to complete the interviews and questionnaires, the
recruiter will administer the Short Blessed Test (SBT) [93]. Patients who
score >16 on the SBT will be exempted from the interviews and
questionnaires due to cognitive impairment; the only data to be obtained
will be extracted from the EMR.
Baseline Medical Data
Baseline medical data will be obtained from the EMR documentation of
the index hospitalization and recorded on the Baseline Medical Form. If
the patient is cognitively intact, the interviewer will review the medical
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data with the participant and use self-reported data to augment the EMR
data.
The initial diagnosis of HF will be classified as within the past year or
more than one year ago. NYHA class for the past two weeks will be
determined by interview if possible or estimated from the EMR if
necessary. The Rockwood et al. Frailty scale [94] will be used to rate the
patient’s frailty level, with scores ranging from 1 (very fit) to 7 (severely
frail). The rating will be based on a review of the EMR data and the
baseline assessments. The comorbidities and procedures listed in Table 1
will be documented.
Table 1. Medical comorbidities and procedures to be documented based on EMR data at index.
Condition or Procedure

Coding 1

Hypertension

Absent/present

Hyperlipidemia

Absent/present

History of tobacco smoking or vaping

Never, current, past

Coronary artery disease

Absent/present

History of MI or unstable angina

Absent/present (past and/or index)

Cardiomyopathy (amyloid, dilated, drug or alcohol-related,
hypertrophic, ischemic, nonischemic, restrictive, other)
Atrial fibrillation or flutter

1

Absent/present
Absent/present

History of infective endocarditis

Absent/present

Pacemaker

Absent/present

Automatic implantable cardioverter defibrillator (AICD)

Absent/present; ever fired yes/no

History of percutaneous coronary intervention (PCI)

Absent/present (past and/or index)

History of coronary artery bypass graft (CABG) surgery

Absent/present (past and/or index)

Valve disease (>moderate, not tricuspid)

Absent/present

Valve surgery

Absent/present

Left ventricular assist device (LVAD)

Absent/present

Pulmonary hypertension

Absent/present

Chronic obstructive pulmonary disease

Absent/present

Asthma

Absent/present

Sleep apnea

Absent/present

Cerebrovascular accident (stroke)

Absent/present

Diabetes

Absent/present

Autoimmune disease

Absent/present

Peripheral artery disease

Absent/present

Venous disease

Absent/present

Osteoarthritis

Absent/present

Malignancy in past 5 years (excluding basal cell)

Absent/present

Thyroid disease

Absent/present

Chronic kidney disease stage >3

Absent/present

Cirrhosis

Absent/present

Positive COVID test (ever)

Absent/present

Obesity

Absent/present

Response options also include “unknown” and, where appropriate, “refused”.
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When available, the following lab values will be obtained from the
index hospitalization record: Brain natriuretic peptide (BNP), N-terminal
pro-brain natriuretic peptide (NT-proBNP), blood urea nitrogen (BUN),
creatinine, estimated glomerular filtration rate (eGFR), and hemoglobin. If
a test is repeated during the hospital stay, only the initial value will be
recorded.
The index hospitalization record will be examined to determine
whether a toxicology screen was performed during this hospitalization or
in the emergency department. The presence or absence of substances
listed in Table 2 will be noted.
Table 2. Substances that will be recorded if documented on toxicology testing during the hospitalization.
Substances of Interest
Amphetamine

Cocaine metabolites

Opiates

Barbiturates

Ethanol

Oxycodone

Benzodiazepine

Fentanyl

Phencyclidine

Cannabinoids

Methadone

Other

Echocardiographic data will also be obtained from the EMR.
Echocardiography findings the index hospitalization will be obtained if
available; if not, the most recent echocardiogram performed within the
past year will be used. Data to be recorded, when available, include left
ventricular ejection fraction (LVEF), pulmonary artery systolic pressure,
valve dysfunction, diastolic dysfunction, right ventricular dysfunction.
Baseline Psychosocial and Functional Data
Social determinants of health
Various instruments for documenting SDOH have been used in recent
studies (e.g., [95–97]). Because a well-validated and widely-used
instrument was not available, we developed the Heart Failure Social
Determinants of Health (HF-SDOH) form (included in the Supplement).
The items are based on ICD-10 “Z” codes and items assessed in previous
studies. It is divided into the following sections: (1) Demographics, (2)
Education, (3) Employment and Unemployment, (4) Income and Savings,
(5) Problems Related to Housing and Economic Circumstances, (6)
Problems Related to Social Environment or Upbringing, Problems Related
to Family and/or Primary Support Group, (7) Legal and Social Problems,
and (8) Problems Related to Health Care.
Many items are coded in terms of whether the problem was present
during the following time frames: (1) within the past 2 months, (2) within
the past 2 years, (3) more than 2 years ago. The “past 2 months” code is
intended to reflect problems that are currently present or that have
occurred in the recent past. The “within past 2 years” code covers
problems that occurred between about 2 and 24 months ago. Thus, both,
neither, or just one of the 2-month and 2-year codes may be checked for a
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given problem. For example, if a patient became homeless for the first time
within the past month, “within past 2 months” would be checked, but
“within past 2 years” would not be checked. Conversely, if the patient was
homeless around a year ago but currently has stable housing, “within past
2 years” would be checked but “within past 2 months” would not be
checked. Both would be checked if the patient is currently homeless and
has been for a year or two.
The HF-SDOH is administered as a semi-structured interview. The
interviewer asks a general but tailored question for each section and
follows up as needed with more specific probes. For example, the
interview starts with Employment and Unemployment section with a
general question about current employment status. If the patient reports
being retired, additional questions about work-related problems will be
asked in terms of difficulties that may have occurred in the past, e.g.,
having to work multiple jobs. In contrast, the questioning would cover
both past and present for a currently employed patient.
The HF-SDOH asks about current stressors but not about perceived
stress. The 10-item Perceived Stress Scale (PSS) [98] was added to the
protocol in response to reviewers’ recommendations. This change was
implemented in April 2021, after enrollment had already started.
Psychiatric comorbidities
After completing the HF-SDOH interview, the interviewer will
administer selected modules from the NETSCID-5 interview [99] to assess
psychiatric disorders according to the criteria of the 5th edition of the
American Psychiatric Association Diagnostic and Statistical Manual (DSM5) [100]. The disorders to be assessed were found in previous studies to be
prevalent in HF or coronary heart disease, are associated with the
development of HF, and/or are known to complicate HF. Table 3 lists the
disorders of interest.
Table 3. DSM-5 psychiatric comorbidities to be assessed via the NETSCID-5 interview.
Disorder

Disorder

Schizophrenia

Posttraumatic Stress Disorder

Schizoaffective Disorder

Acute Stress Disorder

Bipolar I Disorder

Insomnia Disorder

Bipolar II Disorder

Alcohol Use Disorder

Cyclothymic Disorder

Cannabis Use Disorder

Major Depressive Disorder

Phencyclidine Use Disorder

Persistent Depressive Disorder (dysthymia)

Inhalant Use Disorder

Panic Disorder

Opioid Use Disorder

Agoraphobia

Sedative, Hypnotic, Or Anxiolytic Use Disorder

Generalized Anxiety Disorder

Stimulant Use Disorder
Tobacco Use Disorder
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Heart failure self-care
The revised Self-Care of Heart Failure Index (SCHFI v7.2) [101] will be
administered to assess the quality of HF self-care during the past month.
The SCHFI is well validated and is one of the most widely-used measures
of heart failure self-care. It consists of 29 items divided into 3 scales that
measure (1) self-care maintenance, (2) symptom perception, and (3) selfcare management. Higher scores reflect better self-care.
The Maintenance scale assesses behaviors that patient with HF use to
maintain health or prevent new or worsening medical problems, such as
engaging in exercise, adhering to a low-salt diet, and taking medications as
prescribed. The Symptom Perception scale assess changes that patients with
HF commonly monitor, such as weight, ankle swelling, and shortness of
breath on exertion. The Management scale assesses behaviors that patients
with HF often use to control or respond to symptoms, such as reducing salt
and fluid intake or calling a healthcare provider for guidance.
PROMIS measures
Three Patient-Reported Outcomes Measurement Information System
(PROMIS) short-form questionnaires will also be administered at baseline.
First, the 10-item PROMIS Global Health v1.2 short form [102] will be
administered to assess global perceived physical, mental, and social health
and health-related quality of life. This instrument will provide the data for
the global perceived health outcome.
Second, the 4-item PROMIS Self-Efficacy for Managing Medications and
Treatment short form [103] will be used to assess the patient’s confidence
in his or her ability to manage medications. The data from this instrument
will provide some additional information about self-care that is not
captured on the SCHFI.
Third, 8-item the PROMIS Self-Efficacy for Managing Daily Activities
short form [103] will be used to assess instrumental activities of daily
living. The data from this instrument will provide information about
functional impairment that will complement the NYHA and frailty ratings.
Follow-up Data
Patient readmissions
One of the revised aims of the study is to examine the effects of SDOH
and psychiatric comorbidities on multiple readmissions. We will use the
EMR to identify the dates of admission and discharge for every
readmission to Barnes-Jewish Hospital or to affiliated hospitals during
throughout the follow-up phase of the project. We will also ask patients
who receive care at Veterans Administration facilities to sign a release of
information for to enable us to obtain records of admissions to these
facilities.
The limitation of this approach is that we will not be able to identify
and document all readmissions to hospitals that are not affiliated with
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Barnes-Jewish Hospital or with the Veterans Administration. In previous
studies, we contacted patients on a regular schedule during the follow-up
phase and asked them to identify any readmissions that have occurred
during the interval since the previous contact. We then asked them to sign
release of information forms so that we could obtain records of these
readmissions.
That approach will not be feasible in this study because the eligibility
criteria are very broad. As a result, we expect the cohort to include patients
who are homeless, who have unstable housing arrangements, and/or
whose psychosocial problems (e.g., alcohol or substance abuse) will make
them difficult to contact on a regular basis. Thus, we may not be able to
ascertain 100% of the readmissions. In our experience, however, most
readmissions of patients with HF occur at the same hospital as the index
admission. Consequently, we expect to capture most of the readmissions.
Mortality
The EMR will be used to document the dates of deaths that occur during
readmissions to Barnes-Jewish Hospital, affiliated hospitals, or Veterans
Administration hospitals. We will search online obituaries and the Social
Security Death Index to document deaths that occur outside of these
facilities. If feasible, we will also conduct a search of the National Death
Index.
STATISTICAL ANALYSIS PLAN
Data Management
The Research Electronic Data Capture (REDCap) system [104] will be
used for HIPAA-compliant data entry and data management. NetSCID-5
data on stored on a cloud server. The REDCap and NetSCID-5 data will be
exported to SAS© 9.4 datasets (SAS Institute, Inc., Cary NC, USA) for
analyses and quality control reports, including evaluation of model
variable distributions, identification of outliers and invalid values, and
examination of missing data patterns to build efficient multiple
imputation models.
Attrition
Patients with dementia cannot provide reliable responses to interview
questions, and dementia is a rule out criterion for the DSM-5 disorders of
interest. Thus, the psychiatric disorders will be coded “absent” if the
patient has dementia, and the self-management and global health scores
will be estimated from the patient’s clinical status. Thus, there will
effectively be no loss of self-report data in this subgroup.
For participants without dementia, the patient’s direct involvement in
the study will be limited to the baseline interview and questionnaires.
These assessments might be interrupted in some cases, e.g., by precipitous
changes in medical or cognitive status. Based on our previous experience
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with research on patients with HF, we estimate that approximately 5% of
the participants without dementia will be unable to complete the
assessments. Thus, we expect to obtain complete data on n = 508 patients
and will use multiple imputation for data that are likely missing at random
(MAR).
Planned Statistical Analyses
Aim 1. Coprevalence analyses
We will use one-way Chi-square goodness-of-fit tests to identify
comorbidities for which the coprevalence is significantly higher than would be
expected by chance alone. These analyses will be limited to conditions that
occur in >5% of the sample.
Aim 2. Synergistic effects of coprevalent conditions
The coprevalences of comorbid conditions (even the most common ones)
are likely to be too low to support adequately powered interaction tests. As an
alternative, we will create ordinal syndemic exposure factors (SEFs)
representing the number of conditions present in each comorbidity pair (0, 1,
or 2). The relationship between the SEF and the outcome of interest can be
linear or curvilinear; the latter is more consistent with a synergistic effect. The
primary analyses will focus on psychiatric-medical comorbidities and pairs of
psychiatric comorbidities; additional analyses will test syndemic relationships
between pairs of medical comorbidities.
Aim 2a (Revised). Multiple All-Cause Readmissions: We will fit separate
marginal proportional rates models [105] to each pair of coprevalent conditions,
to test the hypothesis that higher SEF scores predict more all-cause hospital
readmissions, after adjusting for covariates that predicted multiple all-cause
readmissions in a previous study (Freedland et al., under review), including age,
New York Heart Association (NYHA) class, diabetes, chronic obstructive
pulmonary disease (COPD), hypertension, and estimated glomerular filtration
rate (eGFR). For any given model, the factors that comprise the SEF will be
excluded from the covariate list. For example, COPD will be removed from the
list of covariates in a model in which the SEF refers to the combination of
depression and COPD. Additional covariables that are needed for Aim 3 (below)
will be added.
Aim 2b. (Revised). Self-Care of Heart Failure: We will regress the
Maintenance, Management, and Confidence scores from the Self-Care of
Heart Failure Index (SCHFI v7.2) on each SEF in one-way analysis of
covariance (ANCOVA) models, adjusting for known correlates of HF selfcare including age, race, education, number of medications, and smoking
status. Additional covariables that are needed for Aim 3 (below) will be
included. Statistical inference will be based on the planned model
contrasts: C1 = µ0 – µ1, C2 = µ0 – µ2, and C3 = µ1 – µ2, where µi represents
the mean response within level i of the SEF.
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Aim 2c. Perceived Global Health: We will regress the 12-item PROMIS Global
Health short form V1.2 on each SEF in one-way analysis of covariance (ANCOVA)
models, adjusting for known correlates of perceived health in patients with HF
including NYHA class, race, and perceived sufficiency of income [106].
Additional covariables that are needed for Aim 3 (below) will be included.
Aim 3. Vulnerable subgroups
Vulnerable subgroups will be defined by race, sex, and social determinants
of health (SDOH). Examples of SDOHs include financial difficulties, limited
access to health care services, and exposure to violence.
Aim 3a. Effects of Race, Sex, and SDOH on Outcomes: Vulnerable subgroups
of patients with HF will be examined in the same models that will be tested for
Aim 2.
Aim 3b. Clustering of Syndemic Conditions within Vulnerable Subgroups:
We will fit proportional odds models to test the relationship of each
vulnerability factor (e.g., race) to each SEF. The odds ratio associated with the
vulnerability factor (ORvf) is the effect of interest.
Aim 4. Effects of syndemic clusters on outcome disparities in vulnerable
subgroups
We will add SEFs to the Aim 3a models. If adding the SEF attenuates the
effect of the vulnerability factor on the outcome, this supports the hypothesis
that the syndemic pair partially accounts for the effect of the vulnerability
factor on the outcome.
Aim 5. Effects of multimorbidity on outcomes
This aim focuses on the effects of the overall burden of multimorbidity on
hospital readmissions, HF self-care, and perceived global health. The Centers
for Medicare & Medicaid Services (CMS) has found that costs and readmissions
are dramatically higher in patients with >6 chronic conditions than patients
who have <6 conditions [87]. Since all participants in this study will have heart
failure, we will reduce the multimorbidity cut point by one to >5 (vs <5)
comorbidities. This categorical variable will be used in the primary analyses
because of the CMS findings and because of the skewness of multimorbidity
counts. The raw counts will be used in secondary analyses, along with the
Charlson and Deyo weighted indices.
Aim 5a. Overall Effects of Multimorbidity: We will use a marginal
proportional rates model to test the hypothesis that multimorbidity is an
independent predictor of hospital readmissions, after controlling for known
predictors including age and NYHA class and excluding comorbidities. We will
use one-way ANCOVAS to examine the effects of multimorbidity on the HF selfcare and global health outcomes.
Aim 5b. Differences in Multimorbidity between Vulnerable Subgroups: We
will use logistic regression models to examine the effect of multimorbidity on
the dichotomous vulnerabilities discussed in Aim 3a.
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Aim 5c. Differences in Multimorbidity as Explanations for Outcome
Disparities: We will use the same analytic approach described in Aim 4 except
that the SEF will be replaced by multimorbidity category.
Exploratory aims
Logistic regression will be used to analyze associations between prevalence
SDOHs and prevalent psychiatric comorbidities. The Liu et al. model will be
used to analyze the relationship between HF self-care and readmissions [105].
LIMITATIONS
The sample will consist of volunteers, so it may not be fully representative
of the HF population. The baseline assessments will not be repeated, so it will
not be possible to detect changes in SDOH or psychiatric comorbidities or
determine how these changes affect HF outcomes. Readmissions that are not
documented in the EMR or that do not occur at Veterans Administration
facilities will not be ascertained.
DISCUSSION
This observational cohort study will be one of the first to examine
relationships between social determinants of health and psychiatric
comorbidities in patients with heart failure, and to investigate their effects
on multiple readmissions, HF self-care, and global health. It will be one of
the first to apply the syndemics framework to research on HF, and to
determine whether the multimorbidity framework offers a more
parsimonious approach than the syndemics framework to predicting HF
outcomes. Many of the SDOH factors and psychiatric comorbidities have
not been studied before in patients with HF.
Since this study is not a trial, the results may not have direct clinical or
public health implications. However, an overarching goal of this project is
to identify problems, or clusters of problems, that are prevalent in patients
with HF, that affect outcomes, and that are not routinely addressed in HF
care. Identification of these problems is a prerequisite for the developing
and testing of interventions designed to treat them. Additional studies will
be needed for these purposes.
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